Ionis and AstraZeneca: Shares Tank as Phase 3 ATTR-CM Trial Falls Short of Expectations
We lower our fair value estimate for Ionis Pharmaceuticals.
Rachel Elfman
Rachel Elfman is an equity analyst for Morningstar.
More From Rachel Elfman
This Cheap Stock to Watch Is Up 65% in 2025
But this top-performing stock still looks 40% undervalued.
